Skip to main content

Aura GT

Small Samples, Big Discoveries

Gain unprecedented insight into gene therapy development with Aura GT. Just 5 µL of sample is all you need to evaluate capsid and viral vector aggregates, so you can identify stability issues early.

Request a Quote

Viral Vector Aggregation

5 µL Volume

DNA Leakage Monitoring

1 Minute Per Sample

Why Choose Aura GT?

There’s no question that adeno-associated viruses (AAVs) have revolutionized gene therapy product development.
But with a limited amount of material available, you may have hesitated about using your precious sample for aggregate testing—until now.
Aura GT is the first and only system designed to detect, count, and characterize AAV particles with just 5 µL.
Combining Backgrounded Membrane Imaging (BMI) with Fluorescence Membrane Microscopy (FMM) dual-channel technology, you can now make confident decisions earlier, so you’re one step closer to success.

Analyze small volumes. You only need 5 µL of sample, which allows you to start characterizing particles in early phase development.

Viral vector characterization and identification. Aura GT makes it simple to distinguish between capsid and non-capsid aggregates. Confirm whether or not DNA leakage is the root cause of aggregation straight from the box.

Learn more with innovative technology. Get the insight you need with Aura GT’s duo of BMI and FMM. Not only can you now avoid tedious, labor-intensive assays, but with Aura GT you can distinguish and characterize different serotypes for aggregation and product features for a deeper understanding of your gene therapy.

Easily Quantify and Identify AAV Particles

AAVs are known to form large, subvisible aggregates that cannot be easily predicted or quantified, making it difficult to assess their impact on patients. To make things even more convoluted, unstable AAVs can aggregate in unpredictable shapes and forms.

Luckily, there’s an easier way to identify and characterize AAV aggregates with Aura GT. Now you can characterize your AAV particles with the lowest volume requirements, highest throughput, and gain insight into their stability.

Identify Root Cause and Characterize AAV Particles at Low Volume

Researchers have long sought to identify the root cause of unstable AAV particles. This challenge has been compounded by legacy systems that are unable to perform low volume SVP analysis or interrogate for DNA content.

In one 5µL assay, Aura GT overcomes this hurdle.

Leverage the power of fluorescent dyes such as Thioflavin T (ThT) and SYBR™ Gold to confidently identify capsid aggregates and DNA in your gene therapy sample with FMM. Make more educated AAV candidate decisions and learn the root causes of aggregation at the very beginning of your process.

Gain Valuable Insights in Hours, Not Months

Get your gene therapy products to market at lightning speed with Aura GT.
Instead of waiting months to see results, Aura GT’s 96-well particle screening assay can give you useful information in just a few hours.
Make direct comparisons between different formulations, AAV serotypes and stability, storage conditions, and lots.